

On page 13, line 21 replace the third paragraph with the following:

Mucosal vaccines and the adjuvant of beta-1,3/beta-1,6 polysaccharide (glucan) can be administered orally, nasally, rectally, vaginally, through gastric administration or any other means by which the vaccine and adjuvant are allowed to come into contact with mucosal surfaces.

IN THE CLAIMS:

Please substitute the following claim for pending claim 1.

1. (Twice amended) A mucosal adjuvant composition that modulates the effect of medicinal substances administered onto mucosal surfaces, the mucosal adjuvant composition comprising a branched beta-1,3-glucan that contains beta-1,3-linked side chains anchored by a beta-1,6-linkage to the beta-1,3-linked chains.

6. (Amended) The composition of claim 1 wherein the substance is mixed with the mucosal adjuvant composition.

7. (Amended) The composition of claim 1 wherein the substance is administrated prior to the mucosal adjuvant composition.

8. (Amended) The mucosal adjuvant composition of claim 1 wherein the substance and the mucosal adjuvant composition are intended for administration as a nasal spray.

Please add the following new claims 14-25:

14. The mucosal adjuvant composition of claim 1 wherein the substance is administrated simultaneously with the mucosal adjuvant composition.

15. The mucosal adjuvant composition of claim 1 wherein the substance is administrated after administration of the mucosal adjuvant composition.

16. The mucosal adjuvant composition of claim 1 wherein the substance and the mucosal adjuvant composition are intended for administration as a nasal drops.

17. A mucosal adjuvant composition that modulates the effect of an influenza virus vaccine administered onto mucosal surfaces, the mucosal adjuvant composition comprising glucose monomers linked together in branched beta-1,3 linked chains with beta-1,3,6 linked branching points comprising beta-1,3 linked or beta 1,6 linked side chains.
18. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine is administrated into the nasal cavity.
19. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine is administrated orally.
20. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine is mixed with the mucosal adjuvant preparation.
21. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine is administrated prior to the mucosal adjuvant composition.
22. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine is administrated simultaneously with the mucosal adjuvant composition.
23. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine is administrated after administration of the mucosal adjuvant composition.
24. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine and the mucosal adjuvant composition are intended for administration as a nasal spray.
25. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine and the mucosal adjuvant composition are intended for administration as a nasal drops.

CLAIMS PENDING IN APPLICATION FOLLOWING ENTRY OF AMENDMENT

1. (Twice amended) A mucosal adjuvant composition that modulates the effect of medicinal substances administered onto mucosal surfaces, the mucosal adjuvant composition comprising a branched beta-1,3-glucan that contains beta-1,3-linked side chains anchored by a beta-1,6-linkage to the beta-1,3-linked chains.
2. The composition of claim 1 wherein the substance is a vaccine formulation.
3. The composition of claim 1 wherein the substance is an influenza virus vaccine.
4. The composition of claim 1 wherein the substance is administrated into the nasal cavity.
5. The composition of claim 1 wherein the substance is administrated orally.
6. (Amended) The composition of claim 1 wherein the substance is mixed with the mucosal adjuvant composition.
7. (Amended) The composition of claim 1 wherein the substance is administrated prior to the mucosal adjuvant composition.
8. (Amended) The mucosal adjuvant composition of claim 1 wherein the substance and the mucosal adjuvant composition are intended for administration as a nasal spray.
14. The mucosal adjuvant composition of claim 1 wherein the substance is administrated simultaneously with the mucosal adjuvant composition.
15. The mucosal adjuvant composition of claim 1 wherein the substance is administrated after administration of the mucosal adjuvant composition.
16. The mucosal adjuvant composition of claim 1 wherein the substance and the mucosal adjuvant composition are intended for administration as a nasal drops.

17. A mucosal adjuvant composition that modulates the effect of an influenza virus vaccine administered onto mucosal surfaces, the mucosal adjuvant composition comprising glucose monomers linked together in branched beta-1,3 linked chains with beta-1,3,6 linked branching points comprising beta-1,3 linked or beta 1,6 linked side chains.
18. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine is administrated into the nasal cavity.
19. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine is administrated orally.
20. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine is mixed with the mucosal adjuvant preparation.
21. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine is administrated prior to the mucosal adjuvant composition.
22. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine is administrated simultaneously with the mucosal adjuvant composition.
23. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine is administrated after administration of the mucosal adjuvant composition.
24. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine and the mucosal adjuvant composition are intended for administration as a nasal spray.
25. The mucosal adjuvant composition of claim 17 wherein the influenza virus vaccine and the mucosal adjuvant composition are intended for administration as a nasal drops.